Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 70

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 70
---
 received a cash fee of 9.0% of the aggregate gross proceeds paid to us for the securities sold in the March 2024 Offerings and reimbursement of certain out-of-pocket expenses. As additional compensation to WallachBeth, in connection with the March 2024 Offerings, we issued to designees of WallachBeth the March 2024 PA Warrants to purchase an aggregate of 32,000 shares of Common Stock, such number of shares equal to two percent (2.0%) of the number of shares of Common Stock issued in the March 2024 RD, at an exercise price per share equal to $1.64, which is equal to the exercise price of the March 2024 Common Warrants.

Weagreed to file a registration statement to register the resale of the March 2024 Common Warrant Shares within 30 days of the date of the March 2024 Purchase Agreement and to use commercially reasonable efforts to keep such registration statement effective at all times until no March 2024 Investor owns any March 2024 Common Warrants or March 2024 Common Warrant Shares. On April 4, 2024, we filed the April 2024 Registration Statement (Registration No. 333-278512), registering the resale of the March 2024 Common Warrant Shares, which was subsequently declared effective by the SEC on April 15, 2024. The April 2024 Registration Statement also registers the resale of the shares of Common Stock issuable upon exercise of the March 2024 PA Warrants.

Terms of the Warrants

The March 2024 Common Warrants are exercisable, at an exercise price of $1.64, commencing on the effective date of stockholder approval of the issuance of the March 2024 Common Warrant Shares upon exercise of the March 2024 Common Warrants, which approval wasobtained on June 4, 2024, and will expire on the fifth anniversary of such date. If at any time after 90 days from the closing of the March 2024 Offerings, a registration statement registering the issuance of the shares of Common Stock underlying the March 2024 Common Warrants under the Securities Act is not effective or available, the holder may, in its sole discretion, elect to exercise the March 2024 Common Warrants through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of Common Stock determined according to the formula set forth in such warrant.